CIN '2007 - 4th CONGRESS OF NEPHROLOGY IN INTERNET
Hemoglobin normalisation and hemodialysis adequacy
Dr. Hadjiyannacos, Dr. Vlassopoulos
Nephrology Departement - A. Fleming Hospital - Athens,
Abstract
Patients with end-stage renal disease often suffer from anemia due mainly to erythropoietin (Epo) deficiency. Anemia correction with Epo treatment has been shown to improve quality of life, physical exercise capacity and ameliorate left ventricular hypertrophy, a well-known risk factor for cardiovascular morbidity and mortality. The optimal target hemoglobin (Hb) level (normal or subnormal) for Epo treatment is a matter of debate. The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) recommends an Hb level of ≥11g/dl with insufficient evidence to routinely maintaining Hb ≥ 13 g/dl (opinion) [1]. The European Best Practice Guidelines (EBPG) suggests an Hb level of >11 g/dl with no upper limit, except for patients with cardiovascular disease and/or diabetes where Hb concentrations >12 g/dl are not recommended.Comments: